Autor: |
Zhao, Yisong, Xue, Yixue, Liu, Yunhui, Fu, Wei, Jiang, Naijia, An, Ping, Wang, Ping, Yang, Zhihang, Wang, Yuqin |
Předmět: |
|
Zdroj: |
British Journal of Neurosurgery; Aug2005, Vol. 19 Issue 4, p322-326, 5p |
Abstrakt: |
In clinical practice there is a difference in response of the blood-tumour barrier (BTB) permeability induced by bradykinin in brain tumours with the same pathology. The variability in response of tumours to bradykinin is likely to be related to the expression level of bradykinin B2 receptor. This study used fresh human glioma samples to determine the expression level of bradykinin B2 receptor on gliomas with different pathological grades. The grade of tumour was classified using the WHO classification. To determine the bradykinin B2 receptor expression level in gliomas, Immunohistochemistry and Western blot methods were used. In 24 cases of gliomas there were eight cases of WHO I glioma, eight cases of WHO II glioma and eight cases of WHO III glioma. Both Western blot and immunohistochemistry showed bradykinin B2 receptors localized on tumour cells, whilst brain cells at the edge of the glioma hardly expressed B2 receptor. There were significant differences of bradykinin B2 receptor expression level among different pathological grades of glioma. The expression of B2 receptor in the three grades of glioma was in the order of WHO I 2 receptor expression level in human glioma may be useful in screening glioma patients to predict whether they will be suitable for opening of the blood -tumour barrier with bradykinin or its analogue. [ABSTRACT FROM AUTHOR] |
Databáze: |
Complementary Index |
Externí odkaz: |
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|